StreetAlpha.app
Home › Stocks › STAA

Staar Surgical Co (STAA)

Healthcare
$24.22
▼ −3.24%
LAST CLOSE · NOV 20

STAAR Surgical makes implantable lenses used in eye surgery to correct vision problems such as nearsightedness. It last closed at $24.22 on Nov 20, down 3.24% on the day. The next earnings report for STAA is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Oct 2026, STAA reported EPS of $0.11 on revenue of $83.4M, with revenue down 12.0% from a year ago. Over its last 8 reports the stock moved an average of 4.9% the session after earnings. Over the last 12 months STAA insiders bought $62.8M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is STAA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold STAA.

Key Stats

Last 12 months
Results
Revenue
$328.3M
+42.4% vs a year ago
Net income
$530K
0.2% margin
EPS (diluted)
$0.01
Free cash flow
$17.8M
5.4% margin
Valuation
Market cap
$1.2B
50.2M shares
P/E
2422.0
Price over 12 month EPS
Price to sales
3.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$133.6M
At Oct 2
Shareholder equity
$376.1M
Shares outstanding
50.2M
At Oct 30
Fiscal year endsJanuary
ExchangeNasdaq
Financials history
FY2021: $230.5M$230.5MFY2021FY2022: $239.4M$239.4MFY2022FY2023: $322.4M$322.4MFY2023FY2024: $313.9M$313.9MFY2024FY2026: $239.4M$239.4MFY2026

From STAA's SEC filings, latest 10-Q for the period ending Oct 2, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · After the close
Reported EPS
$0.11
Quarter ended Oct 2026
Year ago EPS
$0.18
−38.9% on a GAAP basis
Revenue
$83.4M
−12.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.69Dec '24Mar 2025: -$1.10Mar '25Jun 2025: -$0.34Jun '25Sep 2025: $0.18Sep '25Jan 2026: -$0.36Jan '26Apr 2026: $0.10Apr '26Jul 2026: $0.16Jul '26Oct 2026: $0.11Oct '26Latest $0.11
Revenue by quarter
Dec 2024: $49.0MDec '24Mar 2025: $42.6MMar '25Jun 2025: $44.3MJun '25Sep 2025: $94.7MSep '25Jan 2026: $57.8MJan '26Apr 2026: $93.5MApr '26Jul 2026: $93.5MJul '26Oct 2026: $83.4MOct '26Latest $83.4M
How STAA moved after its last 8 reports
Average move the session after a report ±4.9%
Nov 4, 2026After the close−1.7%
Aug 12, 2026After the close−0.3%
May 13, 2026After the close+8.9%
Mar 3, 2026After the close+1.6%
Oct 20, 2025Time not announced+1.2%
Aug 6, 2025After the close+0.2%
May 7, 2025After the close+0.5%
Feb 11, 2025After the close−24.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on STAAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on STAA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on STAA

Technical Analysis

STAA · as of the Nov 20 close · updated each morning
Turning up

The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is fading (RSI 48). The nearest support is the 200 day average at $24.08, and the nearest resistance the swing high (Sep 4) at $24.36.

Short trendBullish
Long trendNeutral
MomentumFading
StretchNormal
VolatilityHigh, 5.0%/day
Key levels
$35.8752 week high+48.1%
$25.2720 day average+4.3%
$24.91Pivot R1+2.8%
$24.39Pivot+0.7%
$24.36Swing high (Sep 4)+0.6%
$24.22Last close
$24.08200 day average−0.6%
$23.90100 day average−1.3%
$23.70Pivot S1−2.1%
$23.26Swing low (Nov 10)−4.0%
$23.1550 day average−4.4%
$15.5952 week low−35.6%
Indicators
RSI (14)47.62Middle of its rangeNeutral
MACD0.57Below its signal lineBearish
Stochastic25.5Middle of its rangeNeutral
ADX (14)27.8Trending up
Williams %R-84.8Oversold below −80, overbought above −20Oversold
CCI (20)-67.9Oversold below −100, overbought above 100Neutral
Rate of change−3.9%Change over 10 sessionsBearish
ATR (14)$1.21Typical daily range, 5.0% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for STAA

What happened before

See how STAA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow STAA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How STAA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for STAAHow many large options trades hit STAA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

STAA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●93 buying vs 106 selling
  • ▼Held by funds -9.4 pts
  • ▼Funds holding -5
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding197202−2.5%
In funds' top 1036−50.0%
Held by funds100.6%110.0%−9.4 pts
New / increased34 / 5946 / 58−10.6%
Reduced / sold out64 / 4255 / 32+21.8%
Put/call ratio0.840.87−2.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See STAA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

STAA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$62.8M4 buys · 2 insiders
Sold$00 sales · 0 insiders
2026-01 bought $9.4M2026-03 bought $12.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 13Broadwood Capital Inc10% ownerBuy670,213$18.31$12.3M
Jan 9Neal C Bradsher10% ownerBuy27,485$22.05$606K
Jan 8Neal C Bradsher10% ownerBuy406,653$21.68$8.8M
Nov 21, 2025Neal C Bradsher10% ownerBuy1,500,000$27.37$41.1M
Apr 10, 2025Neal C Bradsher10% ownerBuy187,227$15.31$2.9M
Apr 7, 2025Broadwood Partners, L.P.10% ownerBuy845,220$16.12$13.6M
Every insider buy and sale for STAA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See STAA insider trades →

From SEC Form 4 filings by STAA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STAA is in one of them and how their past STAA trades turned out.

STAA in the AI portfolios
Loading…

STAA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered STAA in an article yet. Here's the latest on the wider market.

STAA in the news

About Staar Surgical

STAAR Surgical designs and makes implantable lenses that are placed inside the eye during refractive surgery to correct vision. Its main product is the Implantable Collamer Lens, used to treat nearsightedness, farsightedness and astigmatism. The company sells its lenses to eye surgeons and patients in many countries, and most of its revenue comes from outside the United States. It is based in Monrovia, California.

Headquarters
Monrovia, CA